kuros
-
Biologics
Kuros receives CE certification for Neuroseal®, a novel dural sealant
Schlieren (Zurich), Switzerland, June 21, 2017 – Kuros Biosciences (SIX:KURN) announced today that it has received CE certification for its…
Read More » -
Biologics
Kuros Acquires Xpand to Form Orthobiologics Firm with Bone Graft Substitute
December 19, 2016 Kuros Biosciences is to acquire Xpand Biotechnology by way of a share-swapping deal structured as an exchange…
Read More » -
Biologics
Kuros to Present at the 2015 Orthopedic Trauma Association Annual Meeting
Kuros Biosurgery AG, a biotechnology company developing novel biomaterials and bioactive-biomaterial combination products, today announces that it has been chosen…
Read More » -
Biologics
Kuros, Synthes to Co-Develop Bioactive Materials for Specified Applications
Swiss biomaterials firm Kuros Biosurgery and Synthes inked a license and development agreement under which they will work together commercialize Kuros’ synthetic matrix technology in specified…
Read More » -
Kuros Announces Allowance of European Patent for Synthetic Biomaterials
Kuros Biosurgery AG, a biotechnology company focused on the development of novel biomaterials and bioactive-biomaterial combination products for trauma, wound…
Read More » -
KUROS REPORTS ONE YEAR DATA FROM PHASE IIB STUDY WITH KUR-111
Zurich, Switzerland, 24 January, 2011 – Kuros Biosurgery AG announced today the one year follow-up results of a Phase IIb clinical…
Read More »